Companies don’t plan to fail when it comes to recruitment, but many fail to plan. What happens if your marketing director resigns? A recruiting plan gives your organization the confidence in knowing that whatever happens, there is a process in…
HOME > REGULATORY
REGULATORY
- MHLW Panel Urges Better Application of Emergency Approval
January 16, 2023
- MHLW Likely to Give Up Submitting Bill to Lift Bans on Cannabis-Derived Drugs
January 13, 2023
- MHLW Planning to Submit 6 Bills in Ordinary Diet Session, “Japan CDC” Plan Included
January 13, 2023
- Japan Panel Recognizes 5 More Deaths Possibly Tied to COVID Vaccines
January 13, 2023
- PMP, Off-Patent Drug Rules to Be Major Topics for 2024 Reform: MHLW Pharma Management Director
January 12, 2023
- Japan to Boost Review of Health Damage Claims for COVID-19 Vaccines
January 12, 2023
- 4 Cases of New COVID Variant XBB.1.5 Confirmed in Japan: Govt
January 12, 2023
- MHLW Taking Public Comments on OTC Access to Emergency Contraceptives
January 6, 2023
- MHLW Eyes April Proposal to Push Generic Industry Shake-Up: Asst. Vice Minister
January 6, 2023
- SCARDA to Fund Vaccine Development by KM Biologics, University of Tokyo for Priority Infectious Diseases
January 6, 2023
- “Pseudonymized Medical Info” to Be Created to Fuel Healthcare Data Use in Filing
January 5, 2023
- Revise Assessment Scheme for Deaths after COVID Shots: MHLW Panel Members
December 28, 2022
- No Add'l Safety Measures for Xocova Needed “at This Time”: MHLW Panel
December 28, 2022
- Japan’s Drug Production Contracts 0.9% to 9.2 Trillion Yen in 2021: MHLW
December 28, 2022
- PMDA Says “Slow Cartagena Review” Is Urban Legend, Set to Dispel Misconception
December 27, 2022
- Rx-to-OTC Switching of Morning After Pills Needs Cautious Approach: Lawmakers
December 27, 2022
- 1.1 Billion Yen for Revenue Guarantee System for Antibiotics: FY2023 Budget
December 27, 2022
- Funding for Drug Supply Info System Nixed for 2nd Year: FY2023 Budget
December 27, 2022
- Japan Approves Sanofi’s PD-1 Inhibitor, Teikoku’s Donepezil Tape and More
December 26, 2022
- Chuikyo Recommends Add-On Fee Premiums Related to Drug Supply Issues
December 26, 2022
ページ
The Liberal Democratic Party (LDP) will wrap up its discussions on the FY2023 tax reform plan within a few days. Some provisions of the R&D tax credit system, which allow drug makers to deduct a portion of R&D expenses from…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…